RXI Pharma (RXII) Tops Q1 EPS by 11c

RXI Pharma (NASDAQ: RXII) reported Q1 EPS of ($0.34), $0.11 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $10 million, versus $34 million reported last year.

For earnings history and earnings-related data on RXI Pharma (RXII) click here.

You May Also Be Interested In

• Stran & Company, Inc. (SWAG) Reports Q2 EPS of $0.02
• Borr Drilling (BORR) Misses Q2 EPS by 69c
• Aardvark Therapeutics (AARD) Tops Q2 EPS by 21c